Example: barber

INTEGRATED ANNUAL REPORT - UCB

• Our Phase 3b study BE RADIANT, comparing bimekizumab to secukinumab for the treatment of adults with modera-te-to-severe plaque psoriasis met its primary and all secon-dary end points, showing superiority to secukinumab. • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) accepted marketing application

Tags:

  Administration, Study

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Advertisement

Related search queries